Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News TCT 2025

TTVR Remains Safe, Effective in Presence of CIED Leads

Todd Neale

October 25, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

News Daily News

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

L.A. McKeown

November 21, 2022

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

DOACs Safe, Effective in Subset of Valvular AF Patients

Shelley Wood

March 31, 2021

News Industry News

NaviGate Cardiac Structures Inc. (“NCSI”) reports world’s first successful transcatheter implantation of 52-mm tricuspid valve into a transplanted-heart patient to correct “torrential” tricuspid regurgitation (TR)

August 30, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Daily News

NeuroARC Proposes New Standards for Assessing Neurologic Damage in CV Clinical Trials

Caitlin E. Cox

February 07, 2017

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

Advertisement

TTVR Remains Safe, Effective in Presence of CIED Leads

CVD Still the Leading Cause of Death and Disease Globally

December 2024 Dispatch for the CV Team

Left-Sided Bioprosthetic Valves Often Dysfunctional in Pregnant Women

Roughly 80% of ESC Guideline Writers Have Financial COIs

DOACs Safe, Effective in Subset of Valvular AF Patients

NaviGate Cardiac Structures Inc. (“NCSI”) reports world’s first successful transcatheter implantation of 52-mm tricuspid valve into a transplanted-heart patient to correct “torrential” tricuspid regurgitation (TR)

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

NeuroARC Proposes New Standards for Assessing Neurologic Damage in CV Clinical Trials

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content